Journal of Skin and Stem Cell

Published by: Kowsar

Complications of Botulinum Toxin-A Injection in an Iranian Population

Marzieh Afrozandeh 1 , Amir Heydariyan 1 and Zahra Azizian 1 , *
Authors Information
1 Dermatologist, Iran University of Medical Sciences, Tehran, Iran
Article information
  • Journal of Skin and Stem Cell: March 2017, 4 (2); e63334
  • Published Online: June 30, 2016
  • Article Type: Research Article
  • Received: May 4, 2016
  • Revised: May 30, 2016
  • Accepted: June 20, 2016
  • DOI: 10.5812/jssc.63334

To Cite: Afrozandeh M, Heydariyan A, Azizian Z. Complications of Botulinum Toxin-A Injection in an Iranian Population, J Skin Stem Cell. 2017 ;4(2):e63334. doi: 10.5812/jssc.63334.

Abstract
Copyright © 2016, Journal of Skin and Stem Cell. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited
1. Background
2. Methods
3. Results
4. Discussion
Acknowledgements
References
  • 1. Winter L, Spiegel J. Botulinum toxin type-A in the treatment of glabellar lines. Clin Cosmet Investig Dermatol. 2009;3:1-4. [PubMed: 21437054].
  • 2. Allergan Inc . Prescribing information for Botox Cosmetic. 2005, [cited 15 December 15]. Available from: http://www.Botox.com.
  • 3. Stephan S, Wang TD. Botulinum toxin: clinical techniques, applications, and complications. Facial Plast Surg. 2011;27(6):529-39. doi: 10.1055/s-0031-1298786. [PubMed: 22205526].
  • 4. Kuehn BM. Studies, reports say botulinum toxins may have effects beyond injection site. JAMA. 2008;299(19):2261-3. doi: 10.1001/jama.299.19.2261. [PubMed: 18492959].
  • 5. Kuehn BM. FDA requires black box warnings on labeling for botulinum toxin products. JAMA. 2009;301(22):2316. doi: 10.1001/jama.2009.780. [PubMed: 19509371].
  • 6. Tsui JK. Botulinum toxin as a therapeutic agent. Pharmacol Ther. 1996;72(1):13-24. doi: 10.1016/S0163-7258(96)00091-5. [PubMed: 8981568].
  • 7. Monheit G, Carruthers A, Brandt F, Rand R. A randomized, double-blind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: determination of optimal dose. Dermatol Surg. 2007;33(1 Spec No):S51-9. doi: 10.1111/j.1524-4725.2006.32332.x. [PubMed: 17241415].
  • 8. Kane MA, Brandt F, Rohrich RJ, Narins RS, Monheit GD, Huber MB, et al. Evaluation of variable-dose treatment with a new U.S. Botulinum Toxin Type A (Dysport) for correction of moderate to severe glabellar lines: results from a phase III, randomized, double-blind, placebo-controlled study. Plast Reconstr Surg. 2009;124(5):1619-29. doi: 10.1097/PRS.0b013e3181b5641b. [PubMed: 19584772].
  • 9. Dysport (abobotulinumtoxin A) [package insert]. Brisbane, CA and Scottsdale AZ: Tercica, Inc (a subsidiary of the Ipsen Group and Medicis Aesthetics Inc); 4-29-2009.
  • 10. FDA requires boxed warning for all botulinum toxin products. FDA News Release 2009 April 30. [cited 15 December]. Available from: http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm149574.htm.
  • 11. Nigam PK, Nigam A. Botulinum toxin. Indian J Dermatol. 2010;55(1):8-14. doi: 10.4103/0019-5154.60343. [PubMed: 20418969].
  • 12. Vartanian AJ, Dayan SH. Complications of botulinum toxin A use in facial rejuvenation. Facial Plast Surg Clin North Am. 2005;13(1):1-10. doi: 10.1016/j.fsc.2004.04.008. [PubMed: 15519923].
  • 13. Alam M, Arndt KA, Dover JS. Severe, intractable headache after injection with botulinum a exotoxin: report of 5 cases. J Am Acad Dermatol. 2002;46(1):62-5. [PubMed: 11756947].
  • 14. Carruthers JA, Lowe NJ, Menter MA, Gibson J, Nordquist M, Mordaunt J, et al. A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol. 2002;46(6):840-9. [PubMed: 12063480].
  • 15. Cote TR, Mohan AK, Polder JA, Walton MK, Braun MM. Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases. J Am Acad Dermatol. 2005;53(3):407-15. doi: 10.1016/j.jaad.2005.06.011. [PubMed: 16112345].
  • 16. Wollina U, Konrad H. Managing adverse events associated with botulinum toxin type A: a focus on cosmetic procedures. Am J Clin Dermatol. 2005;6(3):141-50. doi: 10.2165/00128071-200506030-00001. [PubMed: 15943491].
  • 17. Carruthers A, Carruthers J. A single-center, dose-comparison, pilot study of botulinum neurotoxin type A in female patients with upper facial rhytids: safety and efficacy. J Am Acad Dermatol. 2009;60(6):972-9. doi: 10.1016/j.jaad.2009.01.005. [PubMed: 19467368].
  • 18. Small R. Botulinum toxin injection for facial wrinkles. Am Fam Physician. 2014;90(3):168-75. [PubMed: 25077722].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments